top of page

Thalidomide derivatives degrade BCL-2 by reprogramming the binding surface of CRBN

PROXIDRUGS member Xinlai Cheng and his team published their work on how thalidomide derivatives degrade BCL-2, providing important clues on overcoming cancer therapy resistance in Cell Reports Physical Science.

 

In this study, the scientists explored the mechanisms of modified thalidomide compounds and their unique interactions with the E3 ligase, CRBN, to target and degrade BCL-2 protein. The findings provide new insights into overcoming resistance in cancer therapy, particularly with BCL-2 mutations resistant to current inhibitors.

 

 



Comments


bottom of page